Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "Phase 1b/2 Study of Batiraxcept (AVB-S6-500) as Monotherapy, in Combination With Cabo, and in Combination With Cabo & Nivo in Patients With Advanced/Metastatic ccRCC"

130 views
June 6, 2023
Comments 0
Login to view comments. Click here to Login